Posts Archive

MagnetisMM-9 NCT05014412: Phase 1/2: A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That...

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma...

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in...

NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple...

NCT04879043: Phase 1/2: Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma This study will assess...

NCT04771078: Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial...

NCT04824794: Phase 1/2: GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies GEN3014 Safety Trial in Relapsed or...

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma Blood Cancer J; 2021...

NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma Newly Diagnosed Multiple Myeloma...

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma The purpose of...

Talquetamab Phase 2 A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma A Study of Talquetamab in...

A Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma This is a Phase 1, multicenter, open label, study of...

NCT04354246: Phase 1: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies COM902 (A TIGIT Inhibitor) in Subjects With...

UNIVERSAL Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma...

EQUATE TRIAL EAA181 / EQUATE Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE...

NCT04244656: Phase 1 -A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma This is a...

The clonoSEQ® Watch Registry Real World Observational Study Using clonoSEQ® Next Generation Sequencing in Hematologic Malignancies: The...

MajesTEC1 study A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1) Relapsed & Refractory...

NCT04671251: Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma Phase 1b Study of AEVI-007 in Subjects...